Company Overview and News

Element 25 selling non-core Holleton Gold Project to focus on manganese

Element 25 Ltd (ASX:E25) is selling its non-core Holleton Gold Project in Western Australia to Ramelius Resources Limited’s (ASX:RMS) wholly-owned subsidiary Edna May Operations Pty Ltd (EMO).

Element 25 eyes growth in manganese demand from emerging battery revolution

Element 25 Ltd (ASX:E25) is set to benefit from the strong demand growth forecast for high-purity manganese from the emerging battery revolution.

Montezuma Mining shareholders confirm name change to Element 25

Montezuma Mining Company Ltd (ASX:MZM) has received shareholder approval to change the company’s name and ticker to Element 25 Ltd (ASX:E25).

Montezuma Mining scoping study results support manganese mining operation

Montezuma Mining Company Ltd (ASX:MZM) has received scoping study results for its 100% owned Butcherbird Manganese Project in Western Australia.

Montezuma Mining Company in trading halt ahead of scoping study release

Montezuma Mining Company Ltd (ASX:MZM) has been granted a trading halt by the ASX pending the release of the Butcherbird Manganese Project scoping study.

Montezuma Mining to rename company Element 25

Montezuma Mining Company Ltd (ASX:MZM) is a diversified explorer focused on manganese, cobalt, lithium and gold.

Montezuma Mining prepares to reveal manganese scoping study results

Montezuma Mining Company Ltd (ASX:MZM) is on schedule to release scoping study results this month for its Butcherbird Manganese Project located in Western Australia.

Montezuma Mining does deal with Magmatic Resources for Mt Venn

Montezuma Mining Company Ltd (ASX:MZM) has entered a binding agreement with Magmatic Resources Ltd (ASX:MAG) to sell an exploration tenement at the Mt Venn intrusion, Western Australia.

Related Articles

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...

EKSO: Ekso Bionics Holdings Analysis and Research Report

2018-09-18 - Asif

Overview The company design, develop and sell exoskeleton technology to augment human strength, endurance and mobility. The company's exoskeleton technology serves multiple markets and can be used both by able-bodied users as well as by persons with physical disabilities. Ekso Bionics has sold, rented or leased devices that (a) enable individuals with neurological conditions affecting gait (stroke and spinal cord injury) to rehabilitate and to walk again and (b) allow industrial workers to perform heavy duty work for extended periods. Today, its medical exoskeleton, Ekso GT, is used as a rehabilitation tool to allow physicians and therapists to rehabilitate patients who have suffered a stroke or spinal cord injury. With its unique features designed specifically for hospitals and its proprietary SmartAssist software, Ekso GT allows for the early mobilization of patients, with high step count and high dosage treatments. The intent is to allow the patient’s central nervous syst...

AGRX: Agile Therapeutics Analysis and Research Report

2018-09-18 - Asif

Overview Agile Therapeutics is a forward-thinking women’s healthcare company dedicated to fulfilling the unmet health needs of today’s women. Twirla® and its other current potential product candidates are designed to provide women with contraceptive options that offer greater convenience and facilitate compliance. The company's lead product candidate, Twirla, also known as AG200-15, is a once-weekly prescription contraceptive patch that is at the end of Phase 3 clinical development. Since its inception in 1997, Agile Therapeutics has devoted substantial resources to developing Twirla, building its intellectual property portfolio, business planning, raising capital and providing general and administrative support for these operations. The company incurred research and development expenses of $14.4 million, $20.9 million and $25.6 million during the years ended December 31, 2017, 2016 and 2015, respectively. The company incurred research and development expenses of $2.4 milli...